Skyepharma has successfully developed a number of inhalation products in collaboration with its multinational partners, resulting in approvals in over 60 countries worldwide, including the US. These development programmes have incorporated our proprietary formulation and device technologies, and include Dry Powder Inhaler (DPI) and Metered-Dose Inhaler (MDI) products. The successful development of flutiform® pMDI which is approved and marketed in Europe and Japan is the most recent example.
Skyepharma has also licensed some of its proprietary formulation technologies to facilitate developments by major pharmaceutical companies, such as GlaxoSmithKline.
> Find out more about our inhalation development pipeline
Contact us to find out how we can help you advance your inhalation product development project.